104 related articles for article (PubMed ID: 11497266)
41. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
42. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis.
Xu XC; Sneige N; Liu X; Nandagiri R; Lee JJ; Lukmanji F; Hortobagyi G; Lippman SM; Dhingra K; Lotan R
Cancer Res; 1997 Nov; 57(22):4992-6. PubMed ID: 9371489
[TBL] [Abstract][Full Text] [Related]
43. HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast.
Parrella P; Scintu M; Prencipe M; Poeta ML; Gallo AP; Rabitti C; Rinaldi M; Tommasi S; Paradiso A; Schittulli F; Valori VM; Toma S; Altomare V; Fazio VM
Cancer Lett; 2005 May; 222(1):75-81. PubMed ID: 15837543
[TBL] [Abstract][Full Text] [Related]
44. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
45. Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer.
Esteller M; Guo M; Moreno V; Peinado MA; Capella G; Galm O; Baylin SB; Herman JG
Cancer Res; 2002 Oct; 62(20):5902-5. PubMed ID: 12384555
[TBL] [Abstract][Full Text] [Related]
46. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
47. A novel RARbeta isoform directed by a distinct promoter P3 and mediated by retinoic acid in breast cancer cells.
Peng X; Maruo T; Cao Y; Punj V; Mehta R; Das Gupta TK; Christov K
Cancer Res; 2004 Dec; 64(24):8911-8. PubMed ID: 15604252
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
[TBL] [Abstract][Full Text] [Related]
49. Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.
De Souza Santos E; De Bessa SA; Netto MM; Nagai MA
Int J Oncol; 2008 Jul; 33(1):25-31. PubMed ID: 18575747
[TBL] [Abstract][Full Text] [Related]
50. Lack of RUNX3 inactivation in columnar cell lesions of breast.
Subramaniam MM; Chan JY; Omar MF; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Histopathology; 2010 Oct; 57(4):555-63. PubMed ID: 20955380
[TBL] [Abstract][Full Text] [Related]
51. RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoA.
Liang ZD; Lippman SM; Wu TT; Lotan R; Xu XC
Cancer Res; 2006 Jul; 66(14):7111-8. PubMed ID: 16849557
[TBL] [Abstract][Full Text] [Related]
52. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
[TBL] [Abstract][Full Text] [Related]
53. [Methylation status and protein expression of adenomatous polyposis coli (APC) gene in breast cancer].
Liu Z; Yang L; Cui DX; Liu BL; Zhang XB; Ma WF; Zhang Q
Ai Zheng; 2007 Jun; 26(6):586-90. PubMed ID: 17562262
[TBL] [Abstract][Full Text] [Related]
54. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
55. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
56. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
Lewis CM; Cler LR; Bu DW; Zöchbauer-Müller S; Milchgrub S; Naftalis EZ; Leitch AM; Minna JD; Euhus DM
Clin Cancer Res; 2005 Jan; 11(1):166-72. PubMed ID: 15671542
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
[TBL] [Abstract][Full Text] [Related]
58. Repression of transactivation of the retinoic acid receptor beta2 promoter in human breast cancer cells.
Tsou HC; Yao YJ; Xie XX; Ping XL; Peacocke M
Exp Cell Res; 1998 Nov; 245(1):221-7. PubMed ID: 9828119
[TBL] [Abstract][Full Text] [Related]
59. Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer.
Ivanova T; Petrenko A; Gritsko T; Vinokourova S; Eshilev E; Kobzeva V; Kisseljov F; Kisseljova N
BMC Cancer; 2002 Mar; 2():4. PubMed ID: 11945179
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer.
Widschwendter M; Berger J; Müller HM; Zeimet AG; Marth C
J Mammary Gland Biol Neoplasia; 2001 Apr; 6(2):193-201. PubMed ID: 11501579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
